Cancer Prevention and Control CIRB Meeting Agenda
May 28, 2020

I. Continuing Review

A221602, Olanzapine with or without fosaprepitant for the prevention of chemotherapy induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): A Phase III Randomized, Double Blind, Placebo-Controlled Trial (Protocol Version Date 05/11/20)

II. Continuing Review

NRG-CC003, Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with Or without Hippocampal Avoidance for Small Cell Lung Cancer (Protocol Version Date 02/14/19)

III. Continuing Review

NRG-CC004, Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo for Sexual Desire In Women With Breast or Gynecologic Cancer (Protocol Version Date 06/07/19)

IV. Continuing Review

URCC-16092, Phase II Study of Low-Dose Ibuprofen for Cognitive Problems in Patients with Cancer (Protocol Version Date 04/22/20)

V. Continuing Review

WF-30917CD, A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors (Protocol Version Date 11/20/19)

VI. New Study Review

A191901, Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions (Protocol Version Date 05/12/20)